Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

281. The dental patient on oral anticoagulant medication: a literature review

The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review Kosyfaki P, Att W, Strub JR CRD summary This review concluded that different anticoagulation strategies were associated with varying complications, during dental treatment. There was insufficient evidence to determine the safest successful dental treatment. The authors (...) ’ conclusions were suitably cautious and appropriate, reflecting the limited evidence available. Authors' objectives To evaluate the relationship between anticoagulant medication and dental treatment. Searching PubMed was searched for relevant English-language publications from 1988 to October 2010. Search terms were reported. High-yield journals (not specified) and relevant bibliographies were manually screened. Study selection Eligible for inclusion were studies assessing the relationship between oral

2011 DARE.

282. Oral anticoagulation with warfarin - 4th edition Full Text available with Trip Pro

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) can be found at . The objective of this guideline is to provide healthcare professionals with clear guidance on the indications for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR

2011 British Committee for Standards in Haematology

283. [Biology of haemostasis disorders: lupus anticoagulant detection]

[Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique. [Biology of haemostasis disorders: lupus anticoagulant detection] . Paris: Haute Autorité de Santé (HAS). 2011 Authors' objectives The National Salaried Workers' Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities

2011 Health Technology Assessment (HTA) Database.

284. Safe and Effective Anticoagulation in the Outpatient Setting

Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program Safe and Effective Anticoagulation in the Outpatient Setting: A Systematic Review of the Evidence Department of Veterans Affairs Health Services Research & Development Service February 2011 Investigators: Principal Investigators: Hanna E. Bloomfield, MD, MPH Brent C. Taylor, PhD, MPH Co-Investigators: Ange Krause, MD Preetham Reddy, MD Research Associates: Nancy Greer, PhD Roderick MacDonald, MS (...) Indulis Rutks, BA Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: VA Evidence-based Synthesis Program (ESP) Center Center for Chronic Disease Outcomes Research Minneapolis VA Medical Center Minneapolis, MN Timothy J. Wilt, MD, MPH, Directori Safe and Effective Anticoagulation in the Outpatient Setting Evidence-based Synthesis Program This report is based on research conducted by the Evidence

2011 Veterans Affairs Evidence-based Synthesis Program Reports

285. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement (Abstract)

Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement Self-management improves oral anticoagulation control. Here we provide data of a preplanned interim analysis of very low-dose early self-controlled anticoagulation.In a prospective, randomized, multicenter trial, 1,137 patients performed low-dose international normalized ratio (INR) self-management with a target INR range of 1.8. to 2.8 for aortic valve replacement

2011 EvidenceUpdates Controlled trial quality: uncertain

286. A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting

A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise and timely manner. , April 2019, Issue 152 , March 2019, Issue 151

2011 Veterans Affairs - R&D

287. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. (Abstract)

Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. Use of central venous catheters (CVC) in treatment of children with cancer is associated with infective complications. Current evidence-based guidelines to prevent catheter-related infections are mainly relevant to the adult population. They are not cancer (especially not childhood cancer) specific. Two existing Cochrane reviews have looked (...) at prophylactic antibiotics and anticoagulants to prevent CVC-related infections.The primary objective was to find which interventions, if any, were effective in preventing CVC-related infections in children with cancer. Further objectives were to examine the effectiveness of each intervention in the following subgroups: implanted versus external catheters, haematological versus non-haematological malignancies, and in those receiving haematopoietic stem cell transplants (HSCT) versus no HSCT.We searched

2010 Cochrane

288. Drug and dietary interactions of the new and emerging oral anticoagulants (Abstract)

Drug and dietary interactions of the new and emerging oral anticoagulants Oral warfarin is associated with extensive food and drug interactions, and there is a need to consider such interactions with the new oral anticoagulants (OACs) dabigatran etexilate, rivaroxaban and apixaban. A literature survey was conducted using PubMed, EMBASE and recent abstracts from thrombosis meetings to identify publications related to food, drug and dietary supplement interaction studies with dabigatran etexilate

2010 EvidenceUpdates

289. Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Full Text available with Trip Pro

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy. Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy.To compare the effectiveness of anticoagulant therapies for the treatment of deep vein thrombosis in pregnancy. The anticoagulant drugs included are UFH, low molecular (...) did not identify any eligible studies for inclusion in the review.We identified three potential studies; after assessing eligibility, we excluded all three as they did not meet the prespecified inclusion criteria. One study compared LMWH and UFH in pregnant women with previous thromboembolic events and, for most of these women, anticoagulants were used as thromboprophylaxis. There were only three women who had a thromboembolic event during the current pregnancy and it was unclear whether

2010 Cochrane

290. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

291. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

292. Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures

Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures Patients may not need to stop oral anticoagulant therapy for simple oral surgical procedures ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted (...) anticoagulant therapy for simple oral surgical procedures Ralph Rosenblum Jr. DDS, MHA . Overview Systematic Review Conclusion Patients taking oral anticoagulant therapy [OAT] did not experience a higher risk of post-operative bleeding compared to patients not on OAT or OAT patients who discontinue therapy following simple oral surgical procedures. Critical Summary Assessment The findings suggest that it is not necessary to discontinue OAT for simple oral surgical procedures. Evidence Quality Rating Good

2010 ADA Center for Evidence-Based Dentistry

293. Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient?

Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? – Clinical Correlations Search Chief of Service Rounds: Should You Always Stop Anticoagulating a Bleeding Patient? January 20, 2010 6 min read | | Sites We Follow: Useful Links: Questions? Comments? Contact us! © New York University. All rights reserved. Electronic ISSN 1944-0030. The content of this site is intended for health

2010 Clinical Correlations

294. [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke]

[Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke] Intravenos trombolytisk behandling av hjerneinfarkt i akuttfasen og sekundaer blodproppforebyggende behandling (platehemmende behandling og antikoagulasjonsbehandling) etter hjerneslag [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment (...) ) after stroke] Intravenos trombolytisk behandling av hjerneinfarkt i akuttfasen og sekundaer blodproppforebyggende behandling (platehemmende behandling og antikoagulasjonsbehandling) etter hjerneslag [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke] Wisloff T, Hamidi V, Ringerike T, Harboe I, Klemp M Record Status This is a bibliographic record of a published health technology assessment

2010 Health Technology Assessment (HTA) Database.

295. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Full Text available with Trip Pro

Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R, Virdi G (...) readmission due to bleeding-related complications, while three on LMWH and 11 on warfarin underwent transoesophageal echocardiogram before the procedure. The total costs were £125 for LMWH and £108.5 for warfarin patients (p<0.0001). Authors' conclusions The authors concluded that uninterrupted warfarin was safer and more cost-effective for anticoagulation in catheter ablation for typical atrial flutter, compared with changing to LMWH before the procedure. CRD commentary Interventions: The two options

2010 NHS Economic Evaluation Database.

296. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis

Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

297. Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis

Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

298. Anticoagulation for Venous Thromboembolism

Anticoagulation for Venous Thromboembolism Anticoagulation for Venous Thromboembolism – TheNNTTheNNT Anticoagulation Given for Acute Venous Thromboembolism (Deep Venous Thrombosis and Pulmonary Embolism) Unclear benefits vs. harms In Summary, for those who got the anticoagulation: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death None were helped (life saved, preventing pulmonary embolism) Harms in NNT 0.9% were harmed by a major bleeding event 0.9% were harmed (...) addressing whether anticoagulation improves important clinical outcomes in patients with VTE (Nielson et al., 1994). Subjects were enrolled if they were ambulatory with symptomatic DVT. Half of the 90 subjects also had silent pulmonary emboli. Subjects were randomized to anticoagulation or NSAIDs and there was 1 fatal PE during the study period (anticoagulation group). In 1960, Barritt and Jordan performed a randomized trial evaluating anticoagulation for presumed PE. While the study is often cited

2010 theNNT

299. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Full Text available with Trip Pro

Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk Hawryluk GW, Austin JW, Furlan JC, Lee JB, O'Kelly C, Fehlings MG CRD summary The review acknowledged the low quality of the evidence, but suggested (...) that it may be important to restart anticoagulation earlier than thought previously with the timing and intensity modified based on perceived individual risks. Further research was needed. Evidence limitations suggest that the findings should be interpreted with caution, but the authors' recommendation for further research seems appropriate. Authors' objectives To identify the optimal timing and intensity for anticoagulation re-initiation following central nervous system haemorrhage in patients with high

2010 DARE.

300. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery.

Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. Dentists may not need to lower the patient anticoagulation dose when performing minor dental surgery. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed (...) to lower the patient anticoagulation dose when performing minor dental surgery. Francesco Chiappelli Ph.D; Michael Montgomery DDS; Juan F. Yepes DDS, MD, MPH, FDS RC . Overview Systematic Review Conclusion Continuing the regular dose of warfarin therapy during minor dental surgery does not appear to increase the risk of bleeding compared to discontinuing or reducing the dose. Critical Summary Assessment A limited to RCTs finds that the rates of clinically significant nonmajor bleeding and minor

2009 ADA Center for Evidence-Based Dentistry